– To establish new global partnerships and explore business opportunities in Europe and Latin America through on-site meetings
– To highlight CMO capabilities and advanced formulation technologies for high-quality finished pharmaceutical products

KUHNIL PHARM. (CEO: Lee Han-Guk/Moon Hee-Seok ) announced today that it will participate in CPhI Worldwide 2025, to be held from October 28 to 30 in Frankfurt, Germany.
 

As the world’s largest pharmaceutical exhibition, CPhI serves as a global platform that encompasses the entire pharmaceutical supply chain — including Active Pharmaceutical Ingredients (APIs), Finished Dosage Forms (FDFs), and Contract Manufacturing and Development (CMO/CDMO). This year’s event is expected to attract more than 2,500 companies from over 170 countries.
 

At the event, KUHNIL PHARM. will hold on-site meetings with major partners from Europe, Latin America, and Southeast Asia, with plans to identify new buyers and expand its export and licensing business. The company will place a strong emphasis on showcasing its high-quality formulation technologies and CMO capabilities as part of its global collaboration model.
 

A company representative stated: “CPhI Frankfurt provides an ideal opportunity to gain insight into global pharmaceutical market trends and discover new partnership opportunities.” adding, “Through this exhibition, we aim to accelerate our global expansion and strengthen KUHNIL PHARM.’s international network.”
 

KUHNIL PHARM. continues to expand its global collaborations based on high-value formulation technologies and strong quality competitiveness. The company is currently pursuing a variety of CMO and licensing-out projects, particularly focused on Europe, Latin America, and Southeast Asia.